These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30554986)

  • 1. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
    Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
    Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
    Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
    Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib in
    Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
    Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
    Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
    Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
    Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
    J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
    Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
    Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
    Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
    Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo
    Urbanska EM; Grauslund M; Koffeldt PR; Truelsen SLB; Löfgren JO; Costa JC; Melchior LC; Sørensen JB; Santoni-Rugiu E
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Chen K; Zhang F; Pan G; Sheng J; Ye J; Xu Y; Yu X; Huang Z; Fan Y
    Clin Lung Cancer; 2021 Jan; 22(1):e1-e4. PubMed ID: 32778510
    [No Abstract]   [Full Text] [Related]  

  • 19. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.